1. Academic Validation
  2. 2',6'-Dihalostyrylanilines, pyridines, and pyrimidines for the inhibition of the catalytic subunit of methionine S-adenosyltransferase-2

2',6'-Dihalostyrylanilines, pyridines, and pyrimidines for the inhibition of the catalytic subunit of methionine S-adenosyltransferase-2

  • J Med Chem. 2014 Jul 24;57(14):6083-91. doi: 10.1021/jm5004864.
Vitaliy M Sviripa 1 Wen Zhang Andrii G Balia Oleg V Tsodikov Justin R Nickell Florence Gizard Tianxin Yu Eun Y Lee Linda P Dwoskin Chunming Liu David S Watt
Affiliations

Affiliation

  • 1 Department of Molecular and Cellular Biochemistry, ‡Department of Pharmaceutical Sciences, College of Pharmacy, §Center for Pharmaceutical Research and Innovation, and ∥Markey Cancer Center, University of Kentucky , Lexington, Kentucky 40506-0509, United States.
Abstract

Inhibition of the catalytic subunit of the heterodimeric methionine S-adenosyl transferase-2 (MAT2A) with fluorinated N,N-dialkylaminostilbenes (FIDAS agents) offers a potential avenue for the treatment of liver and colorectal cancers where upregulation of this Enzyme occurs. A study of structure-activity relationships led to the identification of the most active compounds as those with (1) either a 2,6-difluorostyryl or 2-chloro-6-fluorostyryl subunit, (2) either an N-methylamino or N,N-dimethylamino group attached in a para orientation relative to the 2,6-dihalostyryl subunit, and (3) either an N-methylaniline or a 2-(N,N-dimethylamino)pyridine ring. These modifications led to FIDAS agents that were active in the low nanomolar range, that formed water-soluble hydrochloride salts, and that possessed the desired property of not inhibiting the human hERG potassium ion channel at concentrations at which the FIDAS agents inhibit MAT2A. The active FIDAS agents may inhibit Cancer cells through alterations of methylation reactions essential for Cancer cell survival and growth.

Figures
Products